John W Greiner
Overview
Explore the profile of John W Greiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greiner J, Morillon 2nd Y, Schlom J
Immunotargets Ther
. 2021 Jun;
10:155-169.
PMID: 34079772
NHS-IL12 is a novel immunocytokine designed for delivery of IL-12 to the tumor microenvironment (TME). NHS-IL12 consists of two molecules of IL-12 fused to a human IgG1 (NHS76) recognizing DNA/histone...
2.
Morillon 2nd Y, Sabzevari A, Schlom J, Greiner J
Anticancer Res
. 2020 Sep;
40(10):5329-5341.
PMID: 32988851
Investigation of the efficacy and mechanisms of human immuno-oncology agents has been hampered due to species-specific differences when utilizing preclinical mouse models. Peripheral blood mononuclear cell (PBMC) humanized mice provide...
3.
Morillon Y, Smalley Rumfield C, Pellom S, Sabzevari A, Roller N, Horn L, et al.
Front Oncol
. 2020 May;
10:549.
PMID: 32373533
The lack of serial biopsies in patients with a range of carcinomas has been one obstacle in our understanding of the mechanism of action of immuno-oncology agents as well as...
4.
Morillon 2nd Y, Su Z, Schlom J, Greiner J
J Immunother Cancer
. 2019 Jun;
7(1):150.
PMID: 31186063
Background: While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial) human...
5.
Ingersoll M, Li X, Inman B, Greiner J, Black P, Adam R
Bladder Cancer
. 2018 Nov;
4(4):429-440.
PMID: 30417054
The Fourth Annual Albert Institute Bladder Cancer Care and Research Symposium was held from September 14th-16th in Houston, Texas. The symposium covered a range of topics relevant to bladder cancer,...
6.
Morillon 2nd Y, Hammond S, Durham N, Schlom J, Greiner J
Oncotarget
. 2017 Nov;
8(43):73469-73482.
PMID: 29088720
Immunotherapy was significantly enhanced in a murine tumor model by combining a vaccine with a fusion protein designed to target the glucocorticoid-induced tumor necrosis factor (TNF) receptor related gene (GITR)...
7.
Fallon J, Vandeveer A, Schlom J, Greiner J
Oncotarget
. 2017 Apr;
8(13):20558-20571.
PMID: 28423552
The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a...
8.
Jochems C, Hodge J, Fantini M, Fujii R, Morillon 2nd Y, Greiner J, et al.
Oncotarget
. 2016 Nov;
7(52):86359-86373.
PMID: 27861156
Natural killer (NK) cells are known to play a role in mediating innate immunity, in enhancing adaptive immune responses, and have been implicated in mediating anti-tumor responses via antibody-dependent cell-mediated...
9.
Vandeveer A, Fallon J, Tighe R, Sabzevari H, Schlom J, Greiner J
Cancer Immunol Res
. 2016 Feb;
4(5):452-62.
PMID: 26921031
Bacillus Calmette-Guerin (BCG) is the standard of care for intravesical therapy for carcinoma in situ and non-muscle invasive, nonmetastatic human urothelial carcinoma. Although the responsiveness to this immunotherapeutic is believed...
10.
Tucker J, Jochems C, Boyerinas B, Fallon J, Greiner J, Palena C, et al.
Cancer Immunol Immunother
. 2014 Sep;
63(12):1307-17.
PMID: 25186612
The transcription factor brachyury is a major driver of epithelial to mesenchymal transition in human carcinoma cells. It is overexpressed in several human tumor types versus normal adult tissues, except...